ǥ :
|
ȣ - 520844 178 |
Overlapping Sirolimus- versus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions |
고려대학교 구로병원 순환기내과 |
Yong-Jian Li, 나승운, Kang-Yin Chen, Kanhaiya L. Poddar, 박재형, 나진오, 최철웅, |
Background: The clinical and angiographic outcomes after two or more overlapping sirolimus- and paclitaxel- eluting stents implantation in patients (pts) with diffuse long coronary artery lesions, an important off-label usage of drug-elutng stent (DES) is not clarified yet.
Methods: A total of 174 pts who underwent percutaneous coronary intervention (PCI) with overlapping sirolimus- (SES group: Cypher, n=74 pts, 110 lesions) or paclitaxel- eluting stents (PES group: Taxus, n=100 pts, 177 lesions) were enrolled. Angiographic and clinical outcomes at 6 months were evaluated.
Results: Both groups had similar baseline clinical and procedural characteristics. At 6 months,PES group showed a trend towards lower minimum lumen diameter (MLD), (2.06±1.02 vs 2.42±1.01, P=0.078) compared with SES group. Other angiographic outcomes including binary restenosis, restenosis percentage, and late loss as well as clinical outcomes i.e., cardiac death, Q-wave myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR) and MACE were similar.
Conclusions: The angiographic and clinical outcomes at 6 month were similar and favorable in pts with diffuse long lesions undergoing PCI with either Sirolimus- or Paclitaxel- eluting overlapping stenting. Further study with larger study population and longer duration will be needed to get final conclusion.
|
Table: Angiographic and clinical outcomes at 6 months
Variable, n (%) |
SES Group
(n=74pts, 110 lesions) |
PES Group
(n=100pts, 177 lesions) |
P value |
Binary restenosis |
7 (6.4) |
15 (8.5) |
0.513 |
Late loss, (mm) |
0.70±0.73 |
0.85±0.78 |
0.353 |
Restenosis percentage, (%) |
28.35±25.87 |
36.32±29.36 |
0.176 |
Cardiac death |
1 (1.4) |
4(4.0) |
0.396 |
Q-wave MI |
0 (0) |
0 (0) |
1.000 |
TLR |
6 (8.1) |
5 (5.0) |
0.532 |
TVR |
6 (8.1) |
8 (8.0) |
0.979 |
TVR-MACE |
11 (14.9) |
16(16.0) |
0.838 |
Stent thrombosis |
0 (0) |
1(1.0) |
1.000 |
|
|
|